NASDAQ:CMTA - Clementia Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$14.67 +0.67 (+4.79 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$14.67
Today's Range$14.30 - $14.95
52-Week Range$8.10 - $19.58
Volume167,932 shs
Average Volume38,325 shs
Market Capitalization$465.30 million
P/E Ratio-1.85
Dividend YieldN/A
Beta-0.05

Headlines

Clementia Pharmaceuticals (NASDAQ CMTA) News Headlines

Source:
DateHeadline
Clementias palovarotene nabs rare pediatric disease tag for FOPClementia's palovarotene nabs rare pediatric disease tag for FOP
seekingalpha.com - February 11 at 10:59 AM
Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans ProgressivaClementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
finance.yahoo.com - February 11 at 10:59 AM
Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Buy" from BrokeragesClementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 8 at 3:06 AM
Clementia Pharmaceuticals Inc (CMTA) Expected to Post Earnings of -$0.44 Per ShareClementia Pharmaceuticals Inc (CMTA) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - February 3 at 1:08 AM
Clementia Pharmaceuticals Inc (CMTA) Short Interest Down 84.5% in JanuaryClementia Pharmaceuticals Inc (CMTA) Short Interest Down 84.5% in January
www.americanbankingnews.com - January 29 at 1:46 AM
Clementia Pharmaceuticals Inc. (CMTA): Are Hedge Funds Right About This Stock?Clementia Pharmaceuticals Inc. (CMTA): Are Hedge Funds Right About This Stock?
finance.yahoo.com - December 23 at 5:05 PM
What Type Of Shareholder Owns Clementia Pharmaceuticals Inc.’s (NASDAQ:CMTA)?What Type Of Shareholder Owns Clementia Pharmaceuticals Inc.’s (NASDAQ:CMTA)?
finance.yahoo.com - December 11 at 4:55 PM
Clementia Pharma commercial chief bids adieuClementia Pharma commercial chief bids adieu
seekingalpha.com - November 30 at 10:02 AM
Clementia Announces the Departure of Chief Commercial OfficerClementia Announces the Departure of Chief Commercial Officer
finance.yahoo.com - November 30 at 10:02 AM
Clementia Pharmaceuticals: An Enduring Beacon Of OpportunityClementia Pharmaceuticals: An Enduring Beacon Of Opportunity
seekingalpha.com - November 21 at 4:26 PM
Clementia to Present at the Evercore ISI HealthCONx ConferenceClementia to Present at the Evercore ISI HealthCONx Conference
feeds.benzinga.com - November 21 at 7:09 AM
Clementia Reports Third Quarter 2018 Operating Results and Pipeline UpdatesClementia Reports Third Quarter 2018 Operating Results and Pipeline Updates
finance.yahoo.com - November 7 at 9:35 AM
Clementia Pharma readies $50M stock offering; shares down 6% after hoursClementia Pharma readies $50M stock offering; shares down 6% after hours
seekingalpha.com - October 30 at 9:28 AM
Clementia Pharmaceuticals (CMTA) Plans $50M Public Offering of Common SharesClementia Pharmaceuticals (CMTA) Plans $50M Public Offering of Common Shares
www.streetinsider.com - October 30 at 9:28 AM
Clementia prices equity offeringClementia prices equity offering
seekingalpha.com - October 30 at 9:28 AM
Clementia Announces Pricing of Public Offering of Common SharesClementia Announces Pricing of Public Offering of Common Shares
finance.yahoo.com - October 30 at 9:28 AM
Clementia Announces Proposed Public Offering of Common SharesClementia Announces Proposed Public Offering of Common Shares
finance.yahoo.com - October 29 at 4:17 PM
Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Clementia Pharmaceuticals Shares Spike HigherMid-Afternoon Market Update: NASDAQ Down Over 2.5%; Clementia Pharmaceuticals Shares Spike Higher
www.benzinga.com - October 24 at 4:23 PM
Clementia to file U.S. marketing application for palovarotene in H2 2019; shares up 8% after hoursClementia to file U.S. marketing application for palovarotene in H2 2019; shares up 8% after hours
seekingalpha.com - October 24 at 9:30 AM
Biotech Stock Soars 35%: Clementia to File Bone Disorder NDABiotech Stock Soars 35%: Clementia to File Bone Disorder NDA
finance.yahoo.com - October 24 at 9:30 AM
Clementia (CMTA) to Submit a New Drug Application for Palovarotene for Treatment of FOP Based on Positive Phase 2 ResultsClementia (CMTA) to Submit a New Drug Application for Palovarotene for Treatment of FOP Based on Positive Phase 2 Results
www.streetinsider.com - October 23 at 4:19 PM
Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 ResultsClementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results
finance.yahoo.com - October 23 at 4:19 PM
Clementia initiates Phase 1 trial of palovarotene eye drop formulation in healthy volunteersClementia initiates Phase 1 trial of palovarotene eye drop formulation in healthy volunteers
seekingalpha.com - October 2 at 9:14 AM
Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy VolunteersClementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers
finance.yahoo.com - October 2 at 9:14 AM
Clementia Pharma down 9% on updated mid-stage paloverotene dataClementia Pharma down 9% on updated mid-stage paloverotene data
seekingalpha.com - September 26 at 4:25 PM
Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOPClementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP
finance.yahoo.com - September 26 at 9:37 AM
Clementia to Present at ASBMR 2018 and Upcoming Investor ConferencesClementia to Present at ASBMR 2018 and Upcoming Investor Conferences
finance.yahoo.com - September 5 at 9:34 AM
Clementia Pharmaceuticals (CMTA) Reports Complete Enrollment in Phase 3 MOVE Trial for FOPClementia Pharmaceuticals (CMTA) Reports Complete Enrollment in Phase 3 MOVE Trial for FOP
www.streetinsider.com - August 17 at 9:33 AM
Clementia Pharma completes enrollment in late-stage study of paloverotene in FOPClementia Pharma completes enrollment in late-stage study of paloverotene in FOP
seekingalpha.com - August 16 at 9:38 AM
Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOPClementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP
finance.yahoo.com - August 16 at 9:38 AM
Clementia Reports Second Quarter 2018 Operating Results and Pipeline UpdatesClementia Reports Second Quarter 2018 Operating Results and Pipeline Updates
finance.yahoo.com - August 9 at 9:48 AM
Clementia appoints Steve Forte as CFOClementia appoints Steve Forte as CFO
seekingalpha.com - July 14 at 4:49 PM
Clementia Pharmaceuticals (CMTA) Appoints Steve Forte as Chief Financial OfficerClementia Pharmaceuticals (CMTA) Appoints Steve Forte as Chief Financial Officer
www.streetinsider.com - July 14 at 4:49 PM
Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial OfficerClementia Appoints Experienced Financial Executive Steve Forte as Chief Financial Officer
finance.yahoo.com - July 14 at 4:49 PM
Clementia Appoints Industry Executive Shawn Tomasello to its Board of DirectorsClementia Appoints Industry Executive Shawn Tomasello to its Board of Directors
feeds.benzinga.com - July 5 at 6:50 AM
Clementia to Present at the Jefferies 2018 Global Healthcare ConferenceClementia to Present at the Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - May 31 at 9:48 AM
Your Daily Pharma Scoop: Esperion Shows Positive Data, Clementias Palovarotene, Insmeds ALISYour Daily Pharma Scoop: Esperion Shows Positive Data, Clementia's Palovarotene, Insmed's ALIS
seekingalpha.com - May 24 at 4:27 PM
Clementia Pharmaceuticals Inc. (CMTA)Clementia Pharmaceuticals Inc. (CMTA)
finance.yahoo.com - May 23 at 4:31 PM
Clementia Pharmaceuticals (CMTA) Innovating New Treatments For Ultra-rare Bone Disorders And Other Diseases - SlideshowClementia Pharmaceuticals (CMTA) Innovating New Treatments For Ultra-rare Bone Disorders And Other Diseases - Slideshow
seekingalpha.com - May 23 at 4:31 PM
Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOPClementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
finance.yahoo.com - May 23 at 9:13 AM
Clementia Reports First Quarter 2018 Operating Results and Pipeline UpdatesClementia Reports First Quarter 2018 Operating Results and Pipeline Updates
finance.yahoo.com - May 9 at 9:34 AM
Wired News - Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple OsteochondromasWired News - Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple Osteochondromas
finance.yahoo.com - April 24 at 9:30 AM
Clementia launches mid-stage study of palovarotene in pediatric bone tumorsClementia launches mid-stage study of palovarotene in pediatric bone tumors
seekingalpha.com - April 20 at 9:44 AM
Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple OsteochondromasClementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
finance.yahoo.com - April 20 at 9:44 AM
Analyst: Clementia Has Potential To Reach Unmet Market For Rare Bone DiseaseAnalyst: Clementia Has Potential To Reach Unmet Market For Rare Bone Disease
finance.yahoo.com - March 29 at 9:55 AM
Clementia to Present at the Cowen and Company 38th Annual Health Care ConferenceClementia to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:24 AM
Clementia Reports 2017 Operating Results and Business HighlightsClementia Reports 2017 Operating Results and Business Highlights
finance.yahoo.com - February 28 at 4:56 PM
Clementia to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceClementia to Participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:11 AM
Clementia Appoints Industry Veteran Pierre Legault to its Board of DirectorsClementia Appoints Industry Veteran Pierre Legault to its Board of Directors
finance.yahoo.com - January 31 at 9:20 AM
Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaClementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
finance.yahoo.com - December 12 at 9:14 AM
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel